



ASX ANNOUNCEMENT

Lumos announces successful completion of Retail Entitlement Offer

MELBOURNE, Australia (28 June 2022) – Lumos Diagnostics (ASX: LDX), (**Lumos** or the **Company**) is pleased to announce the successful completion of the retail component (“**Retail Entitlement Offer**”) of its fully underwritten entitlement offer (“**Entitlement Offer**”) of new fully paid ordinary shares in Lumos (“**New Shares**”), raising approximately \$3.3 million.

Together with the institutional component of the Entitlement Offer, Lumos has raised a total of approximately \$11.2 million.

The Retail Entitlement Offer closed at 5:00pm (Sydney time) on Thursday, 23 June 2022. Lumos received valid applications from eligible retail shareholders under the Retail Entitlement Offer (**Eligible Retail Shareholders**) for approximately 1.7 million New Shares (being approximately \$0.3 million). In addition, valid applications from Eligible Retail Shareholders for approximately 0.25 million New Shares (for approximately \$0.05 million) were accepted under the Top Up Facility.

Approximately 15.3 million New Shares were not taken up under the Retail Entitlement Offer and will be allocated to sub-underwriters of the Retail Entitlement Offer. Sub-underwriting commitments by institutional investors and Planet Innovation Holdings Limited ACN 152 424 916 (**Planet Innovation**) were scaled back to accommodate take up under the Retail Entitlement Offer. Planet Innovation is expected to hold 32.4% of Lumos shares on completion of the Retail Entitlement Offer.

Approximately 17.2 million New Shares to be issued under the Retail Entitlement Offer are expected to be allotted on Thursday, 30 June 2022 and will trade on the ASX on a normal settlement basis from Friday, 1 July 2022.

Holding statements are expected to be dispatched on Monday, 4 July 2022.

The Equity Raising was fully underwritten by the Joint Lead Managers, Bell Potter Securities Limited and Wilsons Corporate Finance Limited.

Further information about the Retail Entitlement Offer is provided in the ASX announcement, equity raising investor presentation and the prospectus dated 6 June 2022 (**Prospectus**) released to the ASX on Monday, 6 June 2022.

Director participation in the Retail Entitlement Offer

Each of the Australian directors, Bronwyn LeGrice, Catherine Robson and Sam Lanyon (through a trust in his wife's name) applied to take up their entitlements in full (283,787 New Shares in aggregate) under the Retail Entitlement Offer. Further details will be provided to the market through release of relevant Appendix 3Ys. Sam is a director and co-founder of Planet Innovation. Sam's indirect economic interest in Lumos is comprised of a holding of Lumos shares through the above trust (as last disclosed in his Appendix 3Y dated 28 October 2021) and that trust's, and his, holding of securities in Planet Innovation (as referred to in the Company's IPO prospectus dated 7 June 2021). It is expected that on completion of the Retail Entitlement Offer, his indirect economic interest in Lumos will be 3.66% (on an undiluted basis). Lumos director, Larry Mehren, is located in the United States and consequently was not entitled to participate in the Retail Entitlement Offer.

Diagnostics Manufacturing Facility and Innovation Hub

On 2 February 2022 Lumos announced an intended package of support for, and collaboration with, the Victorian State Government to establish a manufacturing capability and noted that for this potential project to proceed to the next step of finalising a legal agreement, Lumos needed to secure approval from the Australian Therapeutic Goods Administration (**TGA**) for over the counter use of its COVID-19 RAT test, CoviDx™. The Company has submitted an application to the TGA with the aim of securing the necessary approvals to market CoviDx™ in Australia and submitted responses to the first round of questions from the TGA on 13 May 2022 as noted in Lumos's release to ASX of 6 June 2022. Although still within the TGA guided timeframes for assessing applications for IVD products, the TGA approval is taking further time than the Company originally anticipated. In view of this Lumos will update the market of any significant developments in relation to this application and project, including expected timing, when able.

Components of working capital

Use of proceeds of the Entitlement Offer are described in section 3.2 of the Prospectus. "Working Capital" as referred to in the Prospectus comprises the following items: Finance, Information Technology, Manufacturing, Technical Operations, Corporate & Administration, Movement in Accounts Receivable, Inventory, Accounts Payable and Other Items, and Operating Lease Payments. The determination of the

components of working capital is consistent with that applied by Lumos in its IPO prospectus dated 7 June 2021 and subsequent Appendix 4C's released to the ASX.

This announcement was approved by the Lumos Disclosure Committee.

-Ends-

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com or febridx.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Matthew Wright – Australia
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 411 137 080
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598

Important Notices

This announcement is issued by Lumos Diagnostics Holdings Limited. This announcement is not a prospectus or offering document under Australian law or under any other law. It is for information purposes only and does not constitute an offer, invitation, solicitation, advice or recommendation to subscribe for, retain or purchase any entitlements or securities in Lumos Diagnostics Holdings Limited in any jurisdiction. This letter does not constitute financial product advice and does not and will not form any part of any contract for the acquisition of Lumos Diagnostics Holdings Limited ordinary shares.

Not for Distribution or Release in the United States

This letter does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of, any person in the United States or in any other jurisdiction in which such an offer would be illegal. The New Shares have not been, nor will be, registered under the U.S. Securities Act of 1933 as amended (U.S. Securities Act) or under the securities laws of any state or other jurisdiction of the United States. The New Shares may not be issued to, purchased or traded by, or taken up by, any person in the United States or any person acting for the account or benefit of a person in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.

Important Notice to Nominees

Because of legal restrictions, you must not send copies of this letter nor any material relating to the Retail Entitlement Offer to any of your clients (or any other person) acting for the account or benefit of any person in any other jurisdiction outside of Australia and New Zealand. Failure to comply with these restrictions may result in violations of applicable securities laws.